X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (138) 138
oncology (114) 114
female (103) 103
aged (91) 91
male (91) 91
middle aged (91) 91
index medicus (81) 81
adult (74) 74
radiotherapy (58) 58
cancer (54) 54
chemotherapy (53) 53
treatment outcome (45) 45
aged, 80 and over (44) 44
neoplasm staging (35) 35
antineoplastic combined chemotherapy protocols - therapeutic use (28) 28
combined modality therapy (27) 27
radiology, nuclear medicine & medical imaging (25) 25
squamous-cell carcinoma (25) 25
prospective studies (24) 24
squamous cell carcinoma (24) 24
care and treatment (23) 23
cisplatin (23) 23
radiation-therapy (22) 22
antineoplastic agents - therapeutic use (21) 21
chemoradiotherapy (21) 21
survival rate (21) 21
therapy (21) 21
carcinoma (20) 20
fluorodeoxyglucose f18 (20) 20
follow-up studies (20) 20
survival (19) 19
carcinoma, squamous cell - therapy (18) 18
prognosis (18) 18
survival analysis (18) 18
carcinoma, squamous cell - radiotherapy (17) 17
head (17) 17
head and neck cancer (17) 17
radiotherapy dosage (17) 17
carcinoma, squamous cell - drug therapy (16) 16
carcinoma, squamous cell - pathology (16) 16
neck-cancer (16) 16
patients (16) 16
positron-emission tomography (16) 16
surgery (16) 16
head and neck neoplasms - radiotherapy (15) 15
hematology, oncology and palliative medicine (15) 15
human-papillomavirus (15) 15
management (15) 15
radiopharmaceuticals (15) 15
randomized-trial (15) 15
research (15) 15
disease-free survival (14) 14
head and neck neoplasms - drug therapy (14) 14
radiation (14) 14
neoplasms - drug therapy (13) 13
tumors (13) 13
analysis (12) 12
cisplatin - administration & dosage (12) 12
head and neck neoplasms - therapy (12) 12
pet (12) 12
carboplatin (11) 11
carboplatin - administration & dosage (11) 11
locally advanced head (11) 11
medicine & public health (11) 11
metastases (11) 11
otorhinolaryngology (11) 11
phase-iii trial (11) 11
positron emission tomography (11) 11
carcinoma, squamous cell - mortality (10) 10
dose fractionation (10) 10
neck (10) 10
oropharyngeal cancer (10) 10
ovarian neoplasms - drug therapy (10) 10
paclitaxel (10) 10
papillomavirus infections (10) 10
pet imaging (10) 10
pharmacology & pharmacy (10) 10
positron-emission-tomography (10) 10
radiation therapy (10) 10
clinical trials (9) 9
head and neck neoplasms - diagnostic imaging (9) 9
head and neck neoplasms - pathology (9) 9
hypoxia (9) 9
immunohistochemistry (9) 9
neoplasm recurrence, local - drug therapy (9) 9
neoplasms (9) 9
oncology, experimental (9) 9
ovarian cancer (9) 9
radiation oncology group (9) 9
retrospective studies (9) 9
trial (9) 9
triazines - administration & dosage (9) 9
young adult (9) 9
cancer patients (8) 8
chemoradiation (8) 8
cisplatin - therapeutic use (8) 8
cohort studies (8) 8
dentistry, oral surgery & medicine (8) 8
drug administration schedule (8) 8
expression (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2018, Volume 379, Issue 4, pp. 341 - 351
Journal Article
Seminars in Cancer Biology, ISSN 1044-579X, 10/2018, Volume 52, Issue Pt 2, pp. 228 - 240
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 13, pp. 1527 - 1533
Purpose PF-00562271 is a novel inhibitor of focal adhesion kinase (FAK). The objectives of this study were to identify the recommended phase II dose (RP2D) and... 
FAK OVEREXPRESSION | INVASIVENESS | MIGRATION | CELLS | HEPATOCELLULAR-CARCINOMA | METASTASIS | ONCOLOGY | PYK2 | PHOSPHORYLATION | CANCER | PROGRESSION | United States | Humans | Middle Aged | Male | Positron-Emission Tomography | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Focal Adhesion Kinase 2 - antagonists & inhibitors | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Enzyme Inhibitors - pharmacokinetics | Focal Adhesion Kinase 2 - metabolism | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Radiopharmaceuticals | Focal Adhesion Kinase 1 - metabolism | Protein Kinase Inhibitors - pharmacokinetics | Drug Administration Schedule | Pyrimidines - administration & dosage | Neoplasms - enzymology | Treatment Outcome | Neoplasms - diagnostic imaging | Sulfonamides - pharmacokinetics | Neoplasms - drug therapy | Canada | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Cytochrome P-450 CYP3A Inhibitors | Cytochrome P-450 CYP3A - metabolism | Pyrimidines - adverse effects | Midazolam - metabolism | Pyrimidines - pharmacokinetics | Sulfonamides - adverse effects | Fluorodeoxyglucose F18 | Aged | Australia | Neoplasm Staging | Neoplasms - pathology | Nonlinear Dynamics | Focal Adhesion Kinase 1 - antagonists & inhibitors | Sulfonamides - administration & dosage | Index Medicus
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2010, Volume 28, Issue 27, pp. 4142 - 4148
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2017, Volume 23, Issue 7, pp. 1862 - 1874
Journal Article
Cancer, ISSN 0008-543X, 05/2014, Volume 120, Issue 10, pp. 1462 - 1470
Journal Article